Mironid
Mironid seeks to become the world leader in cell signaling directed therapeutic development. The Glasgow-based company is building a pipeline of drug development programs that are targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of diseases with high unmet medical need.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.mironid.com
Related News
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
Mironid appoints Dr Catherine Kelleher as CMO
Mironid extends Series A round, raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.